Glofitamab (Columvi®). HTA ID: 23055

Assessment Status Rapid Review Complete
HTA ID 23055
Drug Glofitamab
Brand Columvi®
Indication Glofitamab is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), after two or more lines of systemic therapy.
Assessment Process
Rapid review commissioned 30/08/2023
Rapid review completed 03/10/2023
Rapid review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of glofitamab compared with the current standard of care, on the basis of the proposed price relative to currently available therapies.